Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Diaz-de-Heredia C, Bielorai B
Blood. 2020; 137(12):1582-1590.
PMID: 33067614
PMC: 7995290.
DOI: 10.1182/blood.2020007848.
Fatobene G, Souza G, Rodrigues C, Novis Y, Rocha V
Hematol Transfus Cell Ther. 2020; 43(4):532-536.
PMID: 33055008
PMC: 8573029.
DOI: 10.1016/j.htct.2020.07.008.
Mou S, Huang Y, Rosenbaum A
Antibodies (Basel). 2019; 7(4).
PMID: 31544891
PMC: 6698957.
DOI: 10.3390/antib7040041.
Wynne J, Wright D, Stock W
Blood Adv. 2019; 3(1):96-104.
PMID: 30622147
PMC: 6325303.
DOI: 10.1182/bloodadvances.2018026211.
Guest E, Aplenc R, Sung L, Raimondi S, Hirsch B, Alonzo T
Blood. 2017; 130(7):943-945.
PMID: 28674028
PMC: 5561899.
DOI: 10.1182/blood-2017-01-762336.
Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.
Desjonqueres A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M
Blood Cancer J. 2016; 6(12):e504.
PMID: 27935576
PMC: 5223147.
DOI: 10.1038/bcj.2016.111.
Antibody Based Therapies in Acute Leukemia.
Shah N
Curr Drug Targets. 2016; 18(3):257-270.
PMID: 27593687
PMC: 8335750.
DOI: 10.2174/1389450117666160905091459.
Antibody therapy for pediatric leukemia.
Vedi A, Ziegler D
Front Oncol. 2014; 4:82.
PMID: 24795859
PMC: 4000992.
DOI: 10.3389/fonc.2014.00082.
Immunotherapy for pediatric leukemia.
Shah N, Dave H, Wayne A
Front Oncol. 2013; 3:166.
PMID: 23847759
PMC: 3696894.
DOI: 10.3389/fonc.2013.00166.
Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August K, Narendran A, Neville K
Drugs. 2013; 73(5):439-61.
PMID: 23568274
DOI: 10.1007/s40265-013-0026-2.
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.
Kantarjian H, Thomas D, Wayne A, OBrien S
J Clin Oncol. 2012; 30(31):3876-83.
PMID: 22891271
PMC: 3478578.
DOI: 10.1200/JCO.2012.41.6768.
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Liedtke M, Twist C, Medeiros B, Gotlib J, Berube C, Bieber M
Haematologica. 2011; 97(1):30-7.
PMID: 21993685
PMC: 3248928.
DOI: 10.3324/haematol.2011.045997.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Porter D, Alyea E, Antin J, DeLima M, Estey E, Falkenburg J
Biol Blood Marrow Transplant. 2010; 16(11):1467-503.
PMID: 20699125
PMC: 2955517.
DOI: 10.1016/j.bbmt.2010.08.001.
Application of immunotherapy in pediatric leukemia.
Wayne A
Curr Hematol Malig Rep. 2010; 4(3):159-66.
PMID: 20425429
DOI: 10.1007/s11899-009-0022-5.
Immunotherapy of childhood cancer: from biologic understanding to clinical application.
Wayne A, Capitini C, Mackall C
Curr Opin Pediatr. 2009; 22(1):2-11.
PMID: 19952749
PMC: 2845444.
DOI: 10.1097/MOP.0b013e3283350d3e.
Immune-based therapeutics for pediatric cancer.
Capitini C, Mackall C, Wayne A
Expert Opin Biol Ther. 2009; 10(2):163-78.
PMID: 19947897
PMC: 2809805.
DOI: 10.1517/14712590903431022.
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
Chevallier P, Mahe B, Garand R, Talmant P, Harousseau J, Delaunay J
Int J Hematol. 2008; 88(2):209-211.
PMID: 18668307
DOI: 10.1007/s12185-008-0123-2.
